Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies

The CD38-targeting antibody daratumumab mediates its anti-myeloma activities not only through Fc-receptor-dependent effector mechanisms, but also by its effects on T-cell immunity through depletion of CD38<sup>+</sup> regulatory T-cells, regulatory B-cells, and myeloid-derived suppressor...

Full description

Bibliographic Details
Main Authors: Christie P. M. Verkleij, Amy Jhatakia, Marloes E. C. Broekmans, Kristine A. Frerichs, Sonja Zweegman, Tuna Mutis, Natalie A. Bezman, Niels W. C. J. van de Donk
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cancers
Subjects:
immunotherapy
multiple myeloma
tumor microenvironment
PD-1
PD-L1
CD38
Online Access:https://www.mdpi.com/2072-6694/12/12/3713

Internet

https://www.mdpi.com/2072-6694/12/12/3713

Similar Items